Repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Persistant immunodominant anti-gag SLYNTVATL responses in HIV-patients with up to 7 years of HAART

Židovec Lepej, Snježana and Kosor, Ela and Gagro, Alenka and Vince, Adriana and Remenar, Anica and Poljak, Mario (2006) Persistant immunodominant anti-gag SLYNTVATL responses in HIV-patients with up to 7 years of HAART. Collegium antropologicum, 30 (Suppl.). pp. 33-38. ISSN 0350-6134 (Print)

[img]
Preview
PDF
Download (159Kb) | Preview

    Croatian abstract

    U ovom smo istraživanju analizirali Gag-specifične CD8+ T-limfocite u HIV-bolesnika liječenih HAART-om kao i u neliječenih zaraženih osoba primjenom iTAg MHC tetramera klase 1 (HLA-A*0201) specifičnih za SLYNTVATL. Gag SLYNTVATL-specifične CD8+ T-limfocite dokazali smo u 18 od 26 liječenih bolesnika (medijan 5,2 godine HAART-a) i u 10 od 14 neliječenih pacijenata. Medijan postotka Gag SLYNTVATL-specifičnih CD8+ T-limfocita u liječenih bolesnika bio je 0,10 (raspon 0,00–0,70%). Medijan broja Gag SLYNTVATL-specifičnih CD8+ T-limfocita na 50.000 CD8+ T-limfocita bio je 56,0 stanica (raspon 2,0–344,0 stanica) i nije bio značajno različit u odnosu na neliječene zaražene osobe (p=0,978). Broj Gag SLYNTVATL-specifičnih CD8+ T-limfocita negativno je korelirao s dužinom perioda nemjerljive viremije u plazmi (p=0,02, Rho= –0,430). U liječenih HIV-bolesnika (do 7,7 godina HAART-a) postoji stabilna populacija Gag SLYNTVATL specifičnih CD8+ T-limfocita. Rezultati ovog rada značajni su za analizu liječenjem-potaknute imunološke rekonstitucije te za razvoj novih strategija liječenja u HIV-bolesti.

    English abstract

    We analyzed Gag-specific CD8+ T-cells in HIV-patients on long-term HAART and in untreated chronically-infected patients by using iTAg MHC class I tetramers (HLA-A*0201) specific for SLYNTVATL. Gag SLYNTVATL-specific CD8+ T-cells were detectable in 18 of 26 treated patients (median 5.2 years of HAART) and in 10 of 14 untreated patients. Median percentage of Gag SLYNTVATL-specific CD8+ T-cells in treated patients was 0.10 (range 0.00-0.70%). Median number of Gag SLYNTVATL-specific CD8+ T-cells per 50,000 CD8+ T-cells was 56.0 cells (range 2.0-344.0 cells) and was not significantly different compared with untreated patients (p = 0.978). Numbers of Gag SLYNTVATL-specific CD8+ T-cells were inversely correlated with the duration of undetectable plasma viremia (p = 0.02, Rho = -0.430). Chronically-infected HIV-patients on HAART (for up to 7.7 years) maintained a stable subpopulation of Gag SLYNTVATL-specific CD8+ T-cells. This finding is relevant for the analysis of treatment-induced immune reconstitution and, possibly, for future therapeutic strategies in HIV-disease.

    Item Type: Article
    MeSH: Antiretroviral Therapy, Highly Active ; Gene Products, gag - drug effects - immunology ; HIV Infections - drug therapy - immunology ; HIV-1 - immunology ; HLA-A2 Antigen - blood - drug effects - immunology ; Peptide Fragments - drug effects - immunology ; Adult ; Aged ; Cross-Sectional Studies ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; env Gene Products, Human Immunodeficiency Virus
    Divisions: Katedra za infektologiju
    Depositing User: Boris Čičovački
    Status: Published
    Creators:
    CreatorsEmail
    Židovec Lepej, Snježana
    Kosor, Ela
    Gagro, Alenka
    Vince, Adriana
    Remenar, Anica
    Poljak, Mario
    Date: December 2006
    Date Deposited: 16 Oct 2008
    Last Modified: 23 Sep 2011 18:10
    Subjects: /
    Related URLs:
      URI: http://medlib.mef.hr/id/eprint/487

      Actions (login required)

      View Item

      Document Downloads

      More statistics for this item...